Laura Bonanno

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 389 citations · Full text

Medicine, Oncology, Pharmacology +17

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso et al. · The Oncologist · 2019 · 228 citations

Medicine, Immunology, Oncology +17

Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150

Margherita Ghisi, Alberto Corradin, Katia Basso et al. · Blood · 2011 · 227 citations · Full text

Life Sciences, Developmental Biology, Molecular Biology +14

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó et al. · Clinical Cancer Research · 2014 · 198 citations

Medicine, Genetics, Oncology +15